Herantis Pharma Plc's half year financial report January 1 - June 30, 2017 (unaudited)
Herantis Pharma PlcCompany release August 29, 2017 at 9:00am Drug development progresses towards randomized trials Herantis Pharma Plc's half year financial report January 1 - June 30, 2017 (unaudited) Highlights in January-June 2017 (compared with January-June 2016): · Herantis Pharma's ("Herantis") Phase 1 clinical study with Lymfactin® advanced in March to the highest dose and in June to the last patient cohort. The company announced in June that it had started planning a Phase 2 clinical study. · The Swedish drug and device authority MPA approved in March the first